PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
33920076-6	2021	A sequential strategy using an anti-S assay as screening test and an anti-N as confirmatory assays resulted in a 96.7% PPV and 99.5% NPV, respectively.	DOP protocol	119-122	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	74-75
34029587-3	2021	We confirmed arginine methylation of N protein by immunoblotting viral proteins extracted from SARS-CoV-2 virions isolated from cell culture.	Arginine	13-21	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	37-38
34029587-4	2021	Type I PRMT inhibitor (MS023) or substitution of R95 or R177 with lysine inhibited interaction of N protein with the 5"-UTR of SARS-CoV-2 genomic RNA, a property required for viral packaging.	Lysine	66-72	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	98-99
33688584-3	2021	Comparing to those under trial/temporarily used antivirus drugs (i.e., umifenovir, lopinavir), ceftriaxone, cefotaxime, and cefuroxime show higher binding affinities to the N-terminal domain of N protein (N-NTD), C-terminal domain of N protein (N-CTD), and receptor-binding domain of S protein (S-RBD).	umifenovir	71-81	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	173-174
33270159-0	2021	1H, 13C, and 15N backbone chemical shift assignments of the C-terminal dimerization domain of SARS-CoV-2 nucleocapsid protein.	Hydrogen	0-2	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	105-117
33270159-0	2021	1H, 13C, and 15N backbone chemical shift assignments of the C-terminal dimerization domain of SARS-CoV-2 nucleocapsid protein.	Carbon-13	4-7	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	105-117
33270159-0	2021	1H, 13C, and 15N backbone chemical shift assignments of the C-terminal dimerization domain of SARS-CoV-2 nucleocapsid protein.	15n	13-16	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	105-117
33735408-0	2021	One-pot high-yield synthesis of Pd nanocubes for Pd-Ir nanocube-based immunoassay of nucleocapsid protein from SARS-CoV-2.	Palladium	32-34	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	85-97
33655282-3	2021	Here we report that the SARS-CoV-2 N protein contains GSK-3 consensus sequences and that this motif is conserved in diverse coronaviruses, despite limited overall sequence conservation, raising the possibility that SARS- CoV-2 may be sensitive to GSK-3 inhibitors including lithium.	Lithium	274-281	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	35-36
33688584-3	2021	Comparing to those under trial/temporarily used antivirus drugs (i.e., umifenovir, lopinavir), ceftriaxone, cefotaxime, and cefuroxime show higher binding affinities to the N-terminal domain of N protein (N-NTD), C-terminal domain of N protein (N-CTD), and receptor-binding domain of S protein (S-RBD).	umifenovir	71-81	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	194-195
33688584-3	2021	Comparing to those under trial/temporarily used antivirus drugs (i.e., umifenovir, lopinavir), ceftriaxone, cefotaxime, and cefuroxime show higher binding affinities to the N-terminal domain of N protein (N-NTD), C-terminal domain of N protein (N-CTD), and receptor-binding domain of S protein (S-RBD).	umifenovir	71-81	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	194-195
33688584-3	2021	Comparing to those under trial/temporarily used antivirus drugs (i.e., umifenovir, lopinavir), ceftriaxone, cefotaxime, and cefuroxime show higher binding affinities to the N-terminal domain of N protein (N-NTD), C-terminal domain of N protein (N-CTD), and receptor-binding domain of S protein (S-RBD).	Lopinavir	83-92	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	173-174
33688584-3	2021	Comparing to those under trial/temporarily used antivirus drugs (i.e., umifenovir, lopinavir), ceftriaxone, cefotaxime, and cefuroxime show higher binding affinities to the N-terminal domain of N protein (N-NTD), C-terminal domain of N protein (N-CTD), and receptor-binding domain of S protein (S-RBD).	Lopinavir	83-92	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	194-195
33688584-3	2021	Comparing to those under trial/temporarily used antivirus drugs (i.e., umifenovir, lopinavir), ceftriaxone, cefotaxime, and cefuroxime show higher binding affinities to the N-terminal domain of N protein (N-NTD), C-terminal domain of N protein (N-CTD), and receptor-binding domain of S protein (S-RBD).	Lopinavir	83-92	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	194-195
33688584-3	2021	Comparing to those under trial/temporarily used antivirus drugs (i.e., umifenovir, lopinavir), ceftriaxone, cefotaxime, and cefuroxime show higher binding affinities to the N-terminal domain of N protein (N-NTD), C-terminal domain of N protein (N-CTD), and receptor-binding domain of S protein (S-RBD).	Ceftriaxone	95-106	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	173-174
33688584-3	2021	Comparing to those under trial/temporarily used antivirus drugs (i.e., umifenovir, lopinavir), ceftriaxone, cefotaxime, and cefuroxime show higher binding affinities to the N-terminal domain of N protein (N-NTD), C-terminal domain of N protein (N-CTD), and receptor-binding domain of S protein (S-RBD).	Ceftriaxone	95-106	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	194-195
33688584-3	2021	Comparing to those under trial/temporarily used antivirus drugs (i.e., umifenovir, lopinavir), ceftriaxone, cefotaxime, and cefuroxime show higher binding affinities to the N-terminal domain of N protein (N-NTD), C-terminal domain of N protein (N-CTD), and receptor-binding domain of S protein (S-RBD).	Ceftriaxone	95-106	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	194-195
33688584-3	2021	Comparing to those under trial/temporarily used antivirus drugs (i.e., umifenovir, lopinavir), ceftriaxone, cefotaxime, and cefuroxime show higher binding affinities to the N-terminal domain of N protein (N-NTD), C-terminal domain of N protein (N-CTD), and receptor-binding domain of S protein (S-RBD).	Cefotaxime	108-118	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	173-174
33688584-3	2021	Comparing to those under trial/temporarily used antivirus drugs (i.e., umifenovir, lopinavir), ceftriaxone, cefotaxime, and cefuroxime show higher binding affinities to the N-terminal domain of N protein (N-NTD), C-terminal domain of N protein (N-CTD), and receptor-binding domain of S protein (S-RBD).	Cefotaxime	108-118	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	194-195
33688584-3	2021	Comparing to those under trial/temporarily used antivirus drugs (i.e., umifenovir, lopinavir), ceftriaxone, cefotaxime, and cefuroxime show higher binding affinities to the N-terminal domain of N protein (N-NTD), C-terminal domain of N protein (N-CTD), and receptor-binding domain of S protein (S-RBD).	Cefotaxime	108-118	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	194-195
33688584-3	2021	Comparing to those under trial/temporarily used antivirus drugs (i.e., umifenovir, lopinavir), ceftriaxone, cefotaxime, and cefuroxime show higher binding affinities to the N-terminal domain of N protein (N-NTD), C-terminal domain of N protein (N-CTD), and receptor-binding domain of S protein (S-RBD).	Cefuroxime	124-134	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	173-174
33688584-3	2021	Comparing to those under trial/temporarily used antivirus drugs (i.e., umifenovir, lopinavir), ceftriaxone, cefotaxime, and cefuroxime show higher binding affinities to the N-terminal domain of N protein (N-NTD), C-terminal domain of N protein (N-CTD), and receptor-binding domain of S protein (S-RBD).	Cefuroxime	124-134	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	194-195
33688584-3	2021	Comparing to those under trial/temporarily used antivirus drugs (i.e., umifenovir, lopinavir), ceftriaxone, cefotaxime, and cefuroxime show higher binding affinities to the N-terminal domain of N protein (N-NTD), C-terminal domain of N protein (N-CTD), and receptor-binding domain of S protein (S-RBD).	Cefuroxime	124-134	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	194-195
33477032-9	2021	Therefore the interactions of ATP with the viral RNA and N protein might represent promising targets for design of drugs and vaccines to terminate the pandemic.	Adenosine Triphosphate	30-33	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	50-51
32469265-0	2021	Docking study of chloroquine and hydroxychloroquine interaction with RNA binding domain of nucleocapsid phospho-protein - an in silico insight into the comparative efficacy of repurposing antiviral drugs.	Chloroquine	17-28	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	91-103
33479198-3	2021	Here we demonstrate that the N protein"s central disordered domain drives phase separation with RNA, and that phosphorylation of an adjacent serine/arginine rich region modulates the physical properties of the resulting condensates.	Serine	141-147	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	29-30
33479198-3	2021	Here we demonstrate that the N protein"s central disordered domain drives phase separation with RNA, and that phosphorylation of an adjacent serine/arginine rich region modulates the physical properties of the resulting condensates.	Arginine	148-156	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	29-30
32939952-6	2021	G4-specific compounds, such as PDP (pyridostatin derivative), can stabilize RG-1 G4 and significantly reduce the protein levels of SARS-CoV-2 N by inhibiting its translation both in vitro and in vivo.	pyridostatin	36-48	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	142-143
33140703-7	2022	The five anti-N drugs studied in this work are 4E1RCat, Silmitasertib, TMCB, Sapanisertib, and Rapamycin.	4E1RCat	47-54	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	14-15
33140703-7	2022	The five anti-N drugs studied in this work are 4E1RCat, Silmitasertib, TMCB, Sapanisertib, and Rapamycin.	silmitasertib	56-69	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	14-15
33140703-7	2022	The five anti-N drugs studied in this work are 4E1RCat, Silmitasertib, TMCB, Sapanisertib, and Rapamycin.	Sirolimus	95-104	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	14-15
33824130-12	2020	We have checked Thymoquinone as ligand for various targets of 2019-nCoV (receptor binding domain of spike, RNA polymerase, protease, Nsp9 RNA binding protein, nucleocapsid phosphoprotein, endoribonuclease) by protein-ligand docking server SwissDoc.	thymoquinone	16-28	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	159-171
32493627-7	2020	The N protein is composed of a serine-rich linker region sandwiched between N Terminal Domain (NTD) and C Terminal Domain (CTD).	Serine	31-37	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	4-5
32467359-6	2020	Compared to the amount of RNA in the original sample, TRIzol treatment destroyed 47.54% of the nucleocapsid protein (N) gene and 39.85% of open reading frame (ORF) 1ab.	trizol	54-60	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	27-28
33594363-0	2021	Direct activation of endothelial cells by SARS-CoV-2 nucleocapsid protein is blocked by Simvastatin.	Simvastatin	88-99	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	53-65
33039147-4	2021	Here we report the structural and biophysical characterization of the SARS-CoV-2 N C-terminal domain (CTD), on which both N homo-oligomerization and ssRNA binding depend.	ssrna	149-154	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	81-82
33039147-8	2021	Furthermore, a low-resolution preliminary model of the full-length SARS-CoV N in complex with ssRNA, obtained by cryo-electron microscopy, provides an initial understanding of self-associating and RNA binding functions exerted by the SARS-CoV-2 N.	ssrna	94-99	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	76-77
33289456-9	2022	Molecular dynamics simulation study of NRBD of SARS-CoV-2 nucleocapsid protein-alpha-spinasterol complex and PL-PRO-cycloeucalenol complex displayed strong stability at 300 K. Both these complexes exhibited constant root mean square deviation (RMSDs) of protein side chains and Calpha atoms throughout the simulation run time.	spinasterol	79-96	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	58-70
33412759-8	2020	Among them, the established antiviral drug glycyrrhizic acid and the phytochemical theaflavin can be considered as possible drug compounds against target N protein of SARS-CoV-2 as they showed lower binding affinities.	Glycyrrhizic Acid	43-60	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	154-155
33412759-8	2020	Among them, the established antiviral drug glycyrrhizic acid and the phytochemical theaflavin can be considered as possible drug compounds against target N protein of SARS-CoV-2 as they showed lower binding affinities.	theaflavin	83-93	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	154-155
32640381-7	2020	Caffeic acid and ferulic acid were found to inhibit SARS-CoV-2 membrane protein while the anti-viral agent"s simeprevir and grazoprevir showed a high binding affinity for nucleocapsid protein.	caffeic acid	0-12	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	171-183
32640381-7	2020	Caffeic acid and ferulic acid were found to inhibit SARS-CoV-2 membrane protein while the anti-viral agent"s simeprevir and grazoprevir showed a high binding affinity for nucleocapsid protein.	ferulic acid	17-29	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	171-183
32640381-7	2020	Caffeic acid and ferulic acid were found to inhibit SARS-CoV-2 membrane protein while the anti-viral agent"s simeprevir and grazoprevir showed a high binding affinity for nucleocapsid protein.	Simeprevir	109-119	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	171-183
32640381-7	2020	Caffeic acid and ferulic acid were found to inhibit SARS-CoV-2 membrane protein while the anti-viral agent"s simeprevir and grazoprevir showed a high binding affinity for nucleocapsid protein.	grazoprevir	124-135	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	171-183
32469265-0	2021	Docking study of chloroquine and hydroxychloroquine interaction with RNA binding domain of nucleocapsid phospho-protein - an in silico insight into the comparative efficacy of repurposing antiviral drugs.	Hydroxychloroquine	33-51	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	91-103
32437124-4	2020	We herein report the development of a colorimetric assay based on gold nanoparticles (AuNPs), when capped with suitably designed thiol-modified antisense oligonucleotides (ASOs) specific for N-gene (nucleocapsid phosphoprotein) of SARS-CoV-2, could be used for diagnosing positive COVID-19 cases within 10 min from the isolated RNA samples.	Sulfhydryl Compounds	129-134	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	199-211
32579064-9	2021	HighlightsAsparagus racemosus have antiviral potentialPhytochemicals of Shatavari showed promising in-silico docking and MD resultsAsparaoside-C and Asparoside-F has good binding with target proteinsAsparagus racemosus holds promise as SARS-COV-2 (S) and (N) proteins inhibitor Communicated by Ramaswamy H. Sarma.	asparoside-f	149-161	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	256-257
32437124-4	2020	We herein report the development of a colorimetric assay based on gold nanoparticles (AuNPs), when capped with suitably designed thiol-modified antisense oligonucleotides (ASOs) specific for N-gene (nucleocapsid phosphoprotein) of SARS-CoV-2, could be used for diagnosing positive COVID-19 cases within 10 min from the isolated RNA samples.	Oligonucleotides	154-170	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	199-211
32437124-4	2020	We herein report the development of a colorimetric assay based on gold nanoparticles (AuNPs), when capped with suitably designed thiol-modified antisense oligonucleotides (ASOs) specific for N-gene (nucleocapsid phosphoprotein) of SARS-CoV-2, could be used for diagnosing positive COVID-19 cases within 10 min from the isolated RNA samples.	Oligonucleotides, Antisense	172-176	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	199-211
32511407-8	2020	Using a new application of selective forces on dinucleotides to estimate context driven mutational processes, we find that synonymous mutations seem driven both by the viral codon bias and by the high value of the CpG force in the N protein, leading to a loss in CpG content.	Dinucleoside Phosphates	47-60	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	231-232
32577653-3	2020	To this end, we created a construct expressing recombinant N fused to a N-terminal maltose binding protein tag which helps keep the oligomeric N soluble for purification.	Maltose	83-90	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	72-73
32577653-3	2020	To this end, we created a construct expressing recombinant N fused to a N-terminal maltose binding protein tag which helps keep the oligomeric N soluble for purification.	Maltose	83-90	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	72-73
32714120-5	2020	Using a new application of selective forces on dinucleotides to estimate context driven mutational processes, we find that synonymous mutations seem driven both by the viral codon bias and by the high value of the CpG force in the N protein, leading to a loss in CpG content.	Dinucleoside Phosphates	47-60	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	231-232
33801464-4	2021	Overexpression of SARS-CoV-2 N resulted in the attenuation of retinoic acid inducible gene-I (RIG-I)-like receptor-mediated interferon (IFN) production and IFN-induced gene expression.	Tretinoin	62-75	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	29-30
33821278-4	2021	We found that virus-like particles produced by coexpression of SARS-CoV-2 S, M, E and N proteins contained spike glycoproteins that were extensively modified by complex carbohydrates.	Carbohydrates	169-182	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	86-87
33801464-6	2021	Furthermore, SARS-CoV-2 N inhibited polyinosinic: polycytidylic acid [poly(I:C)]-mediated IFN signaling at the level of Tank-binding kinase 1 (TBK1) and interfered with the association between TBK1 and interferon regulatory factor 3 (IRF3), subsequently preventing the nuclear translocation of IRF3.	Poly C	50-68	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	24-25
33801464-6	2021	Furthermore, SARS-CoV-2 N inhibited polyinosinic: polycytidylic acid [poly(I:C)]-mediated IFN signaling at the level of Tank-binding kinase 1 (TBK1) and interfered with the association between TBK1 and interferon regulatory factor 3 (IRF3), subsequently preventing the nuclear translocation of IRF3.	poly	36-40	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	24-25
33801464-6	2021	Furthermore, SARS-CoV-2 N inhibited polyinosinic: polycytidylic acid [poly(I:C)]-mediated IFN signaling at the level of Tank-binding kinase 1 (TBK1) and interfered with the association between TBK1 and interferon regulatory factor 3 (IRF3), subsequently preventing the nuclear translocation of IRF3.	Iodine	75-76	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	24-25
33801464-6	2021	Furthermore, SARS-CoV-2 N inhibited polyinosinic: polycytidylic acid [poly(I:C)]-mediated IFN signaling at the level of Tank-binding kinase 1 (TBK1) and interfered with the association between TBK1 and interferon regulatory factor 3 (IRF3), subsequently preventing the nuclear translocation of IRF3.	Carbon	77-79	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	24-25
34736125-7	2021	The CDSs for ORF3a, ORF8, nucleocapsid phosphoprotein, and spike glycoprotein were found to evolve at rapid rate.	cdss	4-8	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	26-38
34931184-3	2021	N released by SARS-CoV-2 infected cells or N-expressing transfected cells binds to neighboring cells by electrostatic high-affinity binding to heparan sulfate and heparin, but not other sulfated glycosaminoglycans.	Heparitin Sulfate	143-158	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	0-1
34931184-3	2021	N released by SARS-CoV-2 infected cells or N-expressing transfected cells binds to neighboring cells by electrostatic high-affinity binding to heparan sulfate and heparin, but not other sulfated glycosaminoglycans.	Heparitin Sulfate	143-158	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	43-44
34931184-3	2021	N released by SARS-CoV-2 infected cells or N-expressing transfected cells binds to neighboring cells by electrostatic high-affinity binding to heparan sulfate and heparin, but not other sulfated glycosaminoglycans.	Heparin	163-170	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	0-1
34931184-3	2021	N released by SARS-CoV-2 infected cells or N-expressing transfected cells binds to neighboring cells by electrostatic high-affinity binding to heparan sulfate and heparin, but not other sulfated glycosaminoglycans.	Heparin	163-170	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	43-44
34931195-3	2021	N released by SARS-CoV-2 infected cells or N-expressing transfected cells binds to neighboring cells by electrostatic high-affinity binding to heparan sulfate and heparin, but not other sulfated glycosaminoglycans.	Heparitin Sulfate	143-158	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	0-1
34931195-3	2021	N released by SARS-CoV-2 infected cells or N-expressing transfected cells binds to neighboring cells by electrostatic high-affinity binding to heparan sulfate and heparin, but not other sulfated glycosaminoglycans.	Heparitin Sulfate	143-158	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	43-44
34931195-3	2021	N released by SARS-CoV-2 infected cells or N-expressing transfected cells binds to neighboring cells by electrostatic high-affinity binding to heparan sulfate and heparin, but not other sulfated glycosaminoglycans.	Heparin	163-170	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	0-1
34931195-3	2021	N released by SARS-CoV-2 infected cells or N-expressing transfected cells binds to neighboring cells by electrostatic high-affinity binding to heparan sulfate and heparin, but not other sulfated glycosaminoglycans.	Heparin	163-170	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	43-44
34450201-5	2021	Here, we report a novel interaction between the SARS-CoV-2 nucleoprotein (N) and the cholesterol transporter NPC1.	Cholesterol	85-96	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	74-75
34853366-1	2021	Here, we aimed to evaluate the clinical performance of a novel automated immunoassay HISCL SARS-CoV-2 Antigen assay kit designed to detect the nucleocapsid (N) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).	-cov-2 antigen	95-109	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	157-158
34734665-0	2022	CTD of SARS-CoV-2 N protein is a cryptic domain for binding ATP and nucleic acid that interplay in modulating phase separation.	Adenosine Triphosphate	60-63	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	18-19
34636246-7	2021	Accordingly, MAA/Co2+ was used as a sensing interface to construct a label-free immunoassay for rapid detection of the N protein in SARS-CoV-2.	Carbon Dioxide	17-21	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	119-120
34607201-4	2021	Oligonucleotide primer was chemically immobilized on the flexible transducers for the biorecognition of the nucleocapsid protein (N) gene.	Oligonucleotides	0-15	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	130-131
34841806-3	2021	The N protein sequence was analyzed by bioinformatics technology, expressed in prokaryotic cell and purified by metal ion affinity chromatography column.	Metals	112-117	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	4-5
34841806-6	2021	Among the 4 prepared N protein fragments, the full-length N protein (N419) was selected as the optimized coating antigen, N412 with 0.5 mol/L NaCl was used as the optimal combination; deleting 91-120 amino acids from the N-terminal of N412 reduced non-specific signal by 87.5%.	2-chloro-3-fluoro-5-methylpyridine	235-239	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	21-22
34841806-6	2021	Among the 4 prepared N protein fragments, the full-length N protein (N419) was selected as the optimized coating antigen, N412 with 0.5 mol/L NaCl was used as the optimal combination; deleting 91-120 amino acids from the N-terminal of N412 reduced non-specific signal by 87.5%.	2-chloro-3-fluoro-5-methylpyridine	235-239	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	58-59
34841806-6	2021	Among the 4 prepared N protein fragments, the full-length N protein (N419) was selected as the optimized coating antigen, N412 with 0.5 mol/L NaCl was used as the optimal combination; deleting 91-120 amino acids from the N-terminal of N412 reduced non-specific signal by 87.5%.	2-chloro-3-fluoro-5-methylpyridine	235-239	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	221-222
34817202-4	2022	We found that virus-like particles produced by co-expression of SARS-CoV-2 S, M, E and N proteins contained spike glycoproteins that were extensively modified by complex carbohydrates.	Carbohydrates	170-183	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	87-88
34762662-4	2021	For tryptic peptides of Nucleocapsid protein, the limit of detection was estimated to be in the mid-attomole range (9E-13 g).	Peptides	12-20	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	24-36
34549987-0	2021	Direct activation of endothelial cells by SARS-CoV-2 nucleocapsid protein is blocked by Simvastatin.	Simvastatin	88-99	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	53-65
34760717-8	2021	Since tryptophan is encoded by only one codon, any mutation that occurs at this position would change the amino acid residue, resulting in an unstable N protein.	Tryptophan	6-16	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	151-152
34395929-5	2021	AND-2-HyP-beta-CYD complex exhibited the IC50 of 0.1-mug.mL-1 (E gene) and 0.29-mug.mL-1 (N gene) against SARS-CoV-2 infected Vero6 cells.	and-2-hyp-beta-cyd	0-18	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	90-91
34516120-9	2021	Use of this new framework to design potentially specific suramin analogs is exemplified using the SARS-CoV-2 RNA-dependent RNA polymerase and nucleocapsid protein, identifying leads that might inhibit a wide range of coronaviruses.	Suramin	57-64	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	142-154
34539415-4	2021	Molecular docking analysis revealed strong binding affinities and interactions between the phytocannabinoids and codon mRNAs for ORF1ab, Surface glycoprotein, Envelope protein and Nucleocapsid phosphoprotein from SARS-CoV-2 whole genome which may be due to chemico-biological interactions as a result of nucleophilic/electrophilic attacks between viral nucleotides and cannabinoids.	phytocannabinoids	91-108	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	180-192
34539415-4	2021	Molecular docking analysis revealed strong binding affinities and interactions between the phytocannabinoids and codon mRNAs for ORF1ab, Surface glycoprotein, Envelope protein and Nucleocapsid phosphoprotein from SARS-CoV-2 whole genome which may be due to chemico-biological interactions as a result of nucleophilic/electrophilic attacks between viral nucleotides and cannabinoids.	Cannabinoids	369-381	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	180-192
34445741-12	2021	The motifs of the RDB of SARS-CoV-2 spike, which binds Hb, and the sites of the heme bind-N protein were disclosed.	Heme	80-84	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	90-91
34445741-14	2021	Furthermore, we also identified heme-binding motifs and interaction with hemin in N protein and other structural (S and M) and non-structural (Nsp3 and Nsp7) proteins.	Heme	32-36	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	82-83
34445741-14	2021	Furthermore, we also identified heme-binding motifs and interaction with hemin in N protein and other structural (S and M) and non-structural (Nsp3 and Nsp7) proteins.	Hemin	73-78	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	82-83
35512584-3	2022	In this work, a graphene-based FET which uses a boron and nitrogen co-doped graphene oxide gel (BN-GO gel) transducer functionalized with nucleoprotein antibodies, has been investigated for the detection of SARS-CoV-2 nucleocapsid (N)-protein in buffer.	Graphite	16-24	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	232-233
34336545-1	2021	This study is an attempt to find a suitable therapy using antimicrobial peptides (AMPs) by identifying peptide-protein interaction of AMPs and nucleocapsid protein of SARS and SARS-CoV- 2.	Peptides	72-80	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	143-155
34336545-8	2021	From positive results of dynamic simulation and previously known knowledge that some AMPs interact with the nucleocapsid of coronaviruses, these AMPs might be used as a potential therapeutic agent for the treatment regime of SARS-CoV-2 and SARS infection.	Adenylyl sulfate	85-89	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	108-120
34336545-8	2021	From positive results of dynamic simulation and previously known knowledge that some AMPs interact with the nucleocapsid of coronaviruses, these AMPs might be used as a potential therapeutic agent for the treatment regime of SARS-CoV-2 and SARS infection.	Adenylyl sulfate	145-149	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	108-120
34294141-7	2021	We found Nsp3 interacted with N through its acidic region at N-terminus, while N interacted with Nsp3 through its NTD, which is rich in the basic amino acids.	Amino Acids, Basic	140-157	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	79-80
34356777-4	2021	Amongst all macromolecular targets, the N-terminal domain of the nucleocapsid protein displayed the strongest affinity with teicoplanin showing binding energies of -7.4 and -102.13 kcal/mol, in docking and Prime MM/GBSA, respectively.	Teicoplanin	124-135	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	65-77
34257311-3	2021	Reprogrammed Cas13b effectors targeting accessible regions of Spike and Nucleocapsid transcripts achieved >98% silencing efficiency in virus-free models.	cas13b	13-19	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	72-84
35512584-3	2022	In this work, a graphene-based FET which uses a boron and nitrogen co-doped graphene oxide gel (BN-GO gel) transducer functionalized with nucleoprotein antibodies, has been investigated for the detection of SARS-CoV-2 nucleocapsid (N)-protein in buffer.	Boron	48-53	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	232-233
35512584-3	2022	In this work, a graphene-based FET which uses a boron and nitrogen co-doped graphene oxide gel (BN-GO gel) transducer functionalized with nucleoprotein antibodies, has been investigated for the detection of SARS-CoV-2 nucleocapsid (N)-protein in buffer.	graphene oxide	76-90	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	232-233
35430407-3	2022	We have designed novel immunosensors targeting conserved protein sequences of the N protein of SARS-CoV-2 based on lab-produced and purified anti-SARS-CoV-2 nucleocapsid antibodies that are densely grafted onto various surfaces (diamond/gold/glassy carbon).	Carbon	249-255	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	82-83
35316221-2	2022	We report phase 1/2 trial results of UB-612, a multitope subunit vaccine containing S1-RBD-sFc protein and rationally-designed promiscuous peptides representing Sarbecovirus conserved Th and CTL epitopes on the nucleocapsid (N), membrane (M) and spike (S2) proteins.	BM	37-39	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	211-223
35155879-5	2022	Biosensors based on polypyrrole (PPy), synthesized in both globular and nanotubular (NTs) morphology, and gold nanoparticles (AuNPs) are reported, using a self-assembly monolayer of 3-mercaptopropionic acid and covalently linked SARS-CoV-2 Nucleocapsid protein.	polypyrrole	33-36	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	240-252
35155879-5	2022	Biosensors based on polypyrrole (PPy), synthesized in both globular and nanotubular (NTs) morphology, and gold nanoparticles (AuNPs) are reported, using a self-assembly monolayer of 3-mercaptopropionic acid and covalently linked SARS-CoV-2 Nucleocapsid protein.	3-Mercaptopropionic Acid	182-206	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	240-252
35316221-2	2022	We report phase 1/2 trial results of UB-612, a multitope subunit vaccine containing S1-RBD-sFc protein and rationally-designed promiscuous peptides representing Sarbecovirus conserved Th and CTL epitopes on the nucleocapsid (N), membrane (M) and spike (S2) proteins.	BM	37-39	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	225-226
35548881-6	2022	The tyrosine 109 residue in the NTD of the N protein was used as the center of the ligand binding grid for the docking simulation.	Tyrosine	4-12	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	43-44
35548881-9	2022	In addition, abiraterone acetate significantly decreased the production of N protein and S protein in the SARS-CoV-2-infected Vero E6 cells.	Abiraterone Acetate	13-32	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	75-76
35532092-8	2022	MM-GBSA calculated the binding free energy uncovered that withanolide D, hypericin, and silymarin result in highly stable binding conformations in three different sites of the nucleocapsid protein.	Withanolides	58-69	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	176-188
35532092-8	2022	MM-GBSA calculated the binding free energy uncovered that withanolide D, hypericin, and silymarin result in highly stable binding conformations in three different sites of the nucleocapsid protein.	Deuterium	70-71	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	176-188
35532092-8	2022	MM-GBSA calculated the binding free energy uncovered that withanolide D, hypericin, and silymarin result in highly stable binding conformations in three different sites of the nucleocapsid protein.	hypericin	73-82	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	176-188
35532092-8	2022	MM-GBSA calculated the binding free energy uncovered that withanolide D, hypericin, and silymarin result in highly stable binding conformations in three different sites of the nucleocapsid protein.	Silymarin	88-97	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	176-188
35181310-4	2022	Effect of 2-DG on virus multiplication was evaluated by RT-PCR (N and RdRp genes) analysis, protein expression analysis of Nucleocapsid (N) and Spike (S) proteins and visual indication of cytopathy effect (CPE), The mass spectrometry analysis was performed to examine the 2-DG induced change in glycosylation status of receptor binding domain (RBD) in SARS-CoV-2 spike protein.	Deoxyglucose	10-14	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	64-65
35632716-7	2022	Lastly, we showed that expression of the reporter genes, N gene, gRNA, and sgRNA from the replicon was sensitive to inhibition by Remdesivir.	remdesivir	130-140	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	57-58
35364381-8	2022	Lithium-treated wells showed a significantly higher percentage of monolayer conservation than viral control, particularly at concentrations higher than 6 mmol/L, verified through microscopic observation, the neutral red assay, and the determination of N protein in the supernatants of treated wells.	Lithium	0-7	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	252-253
35403091-12	2022	For E gene and N gene, Remdesivir showed IC50 of 0.15 microM and 0.11 microM respectively, For E gene and N gene, E4 showed IC50 of 1.18 microg and 1.16 microg respectively.	remdesivir	23-33	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	15-16
35181310-4	2022	Effect of 2-DG on virus multiplication was evaluated by RT-PCR (N and RdRp genes) analysis, protein expression analysis of Nucleocapsid (N) and Spike (S) proteins and visual indication of cytopathy effect (CPE), The mass spectrometry analysis was performed to examine the 2-DG induced change in glycosylation status of receptor binding domain (RBD) in SARS-CoV-2 spike protein.	Deoxyglucose	10-14	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	123-135
35043033-5	2022	The detection of SARS-CoV-2 nucleocapsid (N) protein is validated with limits of detection (LoDs) of 0.34 ng/mL (7.44 pM) and 0.14 ng/mL (2.96 pM) in 1x PBS and artificial saliva, respectively.	Lead	153-156	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	42-43
35181310-4	2022	Effect of 2-DG on virus multiplication was evaluated by RT-PCR (N and RdRp genes) analysis, protein expression analysis of Nucleocapsid (N) and Spike (S) proteins and visual indication of cytopathy effect (CPE), The mass spectrometry analysis was performed to examine the 2-DG induced change in glycosylation status of receptor binding domain (RBD) in SARS-CoV-2 spike protein.	Deoxyglucose	10-14	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	137-138
35539693-3	2022	In this work, we report a highly sequence-specific biosensor based on nanocomposites with aggregation-induced emission luminogens (AIEgen)-labeled oligonucleotide probes on graphene oxide nanosheets (AIEgen@GO) for one step-detection of SARS-CoV-2-specific nucleic acid sequences (Orf1ab or N genes).	Oligonucleotides	147-162	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	291-292
35539693-3	2022	In this work, we report a highly sequence-specific biosensor based on nanocomposites with aggregation-induced emission luminogens (AIEgen)-labeled oligonucleotide probes on graphene oxide nanosheets (AIEgen@GO) for one step-detection of SARS-CoV-2-specific nucleic acid sequences (Orf1ab or N genes).	graphene oxide	173-187	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	291-292
35093569-0	2022	Phosphopeptide enrichment using Phos-tag technology reveals functional phosphorylation of the nucleocapsid protein of SARS-CoV-2.	Phosphopeptides	0-14	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	94-106
35455253-0	2022	Intranasal Coronavirus SARS-CoV-2 Immunization with Lipid Adjuvants Provides Systemic and Mucosal Immune Response against SARS-CoV-2 S1 Spike and Nucleocapsid Protein.	lipid adjuvants	52-67	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	146-158
35447882-7	2022	The Ct values of the nucleocapsid gene and envelope gene of SARS-CoV-2 were significantly higher in the aluminium gauze than in the cotton gauze.	Aluminum	104-113	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	21-33
35081679-2	2022	However, it remains challenging for SERS-based biosensors using a sandwiching strategy to detect long-chain nucleic acids such as nucleocapsid (N) gene of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) because the extension of the coupling distance (CD) between the two tethered metallic nanostructures weakens electric field and SERS signals.	sers	36-40	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	130-142
35081679-2	2022	However, it remains challenging for SERS-based biosensors using a sandwiching strategy to detect long-chain nucleic acids such as nucleocapsid (N) gene of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) because the extension of the coupling distance (CD) between the two tethered metallic nanostructures weakens electric field and SERS signals.	sers	36-40	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	144-145
35081679-2	2022	However, it remains challenging for SERS-based biosensors using a sandwiching strategy to detect long-chain nucleic acids such as nucleocapsid (N) gene of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) because the extension of the coupling distance (CD) between the two tethered metallic nanostructures weakens electric field and SERS signals.	sers	344-348	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	130-142
35081679-2	2022	However, it remains challenging for SERS-based biosensors using a sandwiching strategy to detect long-chain nucleic acids such as nucleocapsid (N) gene of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) because the extension of the coupling distance (CD) between the two tethered metallic nanostructures weakens electric field and SERS signals.	sers	344-348	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	144-145
35081679-3	2022	Herein, we report a magnetic-responsive substrate consisting of heteoronanostructures that controls the CD for ultrasensitive and highly selective detection of the N gene of SARS-CoV-2.	Cadmium	104-106	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	164-165
35054314-7	2022	Sequencing revealed that majority of the mutations in the N gene were located in the variable region between positions 193 and 235 aa, inside and nearby the phosphorylated serine-rich region of the protein N.	Serine	172-178	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	58-59
35054314-7	2022	Sequencing revealed that majority of the mutations in the N gene were located in the variable region between positions 193 and 235 aa, inside and nearby the phosphorylated serine-rich region of the protein N.	Serine	172-178	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	206-207